Abcellera Biologics Inc. · NASDAQ:ABCL

Abcellera Biologics — FY2025 Earnings Presentation

15 slides from Abcellera Biologics's earnings presentation, Feb 24, 2026

1. Slide 1: Full Year 2025 Business Update

   FULL YEAR 2025 BUSINESS UPDATE COPYRIGHT © ABCELLERA FEBRUARY 24, 2026

2. Slide 2: Disclaimer

   DISCLAIMER This presentation contains forward-looking statements, including statements made These statements involve risks, uncertainties and other factors that may cause pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act actual results, levels of activity, perfor

3. Slide 3: 2025 Full Year Recap

   2025 FULL YEAR RECAP We successfully transitioned to a clinical-stage biotech while delivering on all corporate priorities and maintaining our strong liquidity position. Full Year 2025 Business Update Completed platform ABCL635 Phase 1 clinical investments by the first Nominated trials initiated (Jun

4. Slide 4: Internal Pipeline

   INTERNAL PIPELINE Two programs in the clinic, two programs in IND/CTA-enabling activities, and 20+ programs in discovery. MOLECULE TARGET THERAPEUTIC AREA STAGE Discovery IND-Enabling Phase 1 Phase 2 Phase 3 Full Year 2025 Business Update ABCL635 NK3R Endocrinology & Women’s Health ABCL575 OX40L Imm

5. Slide 5: Internal Pipeline: ABCL635 NK3R Antagonist

   INTERNAL PIPELINE ABCL635 In Phase 2 clinical trial with readout anticipated NK3R Antagonist in Q3 2026. Success in the Phase 1/2 study would be data that supports our Target Product Profile: Full Year 2025 Business Update A differentiated Dosing flexibility Comparable efficacy safety profile with to app

6. Slide 6: Two readouts in 2026 & potential catalysts in 2027

   Two readouts in 2026 & potential for multiple catalysts in 2027. 2026 2027 Q1 Q2 Q3 Q4 Potential Catalysts in 2027 Readout ABCL635 Phase 1/2 Late stage development of ABCL635 in menopausal VMS Menopausal VMS Full Year 2025 Business Update ABCL635 Initiation of Phase 2 studies of ABCL635 in oncology

7. Slide 7: 2026 Priorities

   2026 PRIORITIES Advance pipeline to key data readouts for ABCL635 and ABCL575, and set up for additional three INDs in 2027. Full Year 2025 Business Update ABCL635 Phase 1 clinical ABCL688 progressing through trials topline readout in H2 2026 IND-enabling studies Nominate at least 1 additional devel

8. Slide 8: Financials Update Full Year 2025

   8 COPYRIGHT © ABCELLERA Full Year 2025 Business Update FINANCIALS UPDATE FULL YEAR 2025

9. Slide 9: We have the capabilities and the capital to execute on our strategy

   ~$700M in available liquidity We have the to execute on our strategy* Full Year 2025 Business Update capabilities and the capital to ~$560M in total cash, cash equivalents, & marketable securities* execute on our strategy. ~$140M in total available government funding* COPYRIGHT © ABCELLERA * As of D

10. Slide 10: Continuing portfolio advances with two AbCellera-led programs in the clinic

    Continuing portfolio advances with two AbCellera-led programs in the clinic. Cumulative # of Cumulative # of Notable Updates on PARTNER-INITIATED PROGRAM STARTS MOLECULES IN THE CLINIC MOLECULES IN THE CLINIC WITH DOWNSTREAMS Full Year 2025 Business Update Partner-led AbCellera-led Molecule This Qua

11. Slide 11: Partner-initiated programs continue to progress towards the clinic

    Partner-initiated programs continue to progress towards the clinic. Cumulative # of PARTNER-INITIATED PROGRAMS WITH DOWNSTREAM PARTICIPATION* 6 Not Expected to Progress AbCellera Leading or Co-Leading Work Full Year 2025 Business Update 14 In Progress 6 Clinical Development 5 Preclinical Development

12. Slide 12: Operating expenses reflect R&D investments

    Operating expenses reflect R&D investments. Revenue USD Operating Expenses USD LICENSING AND ROYALTY RESEARCH & SALES, GENERAL & MILESTONES DEVELOPMENT ADMIN Full Year 2025 Business Update RESEARCH FEES +$19.6M $186.8M $167.3M -$2.3M $85.5M $83.2M $75.1M $46.9M $28.8M $1.0M COPYRIGHT © ABCELLERA $26.

13. Slide 13: Net loss of $146M; equivalent to ($0.49) per share

    Net loss of $146M; equivalent to ($0.49) per share (basic & diluted). Earnings USD NET EARNINGS EARNINGS PER SHARE: Full Year 2025 Business Update BASIC AND DILUTED ($146.4M) ($0.49) ($162.9M) ($0.55) 2024 2025 2024 2025 COPYRIGHT © ABCELLERA 13

14. Slide 14: Approximately $560M in total cash, equivalents, and marketable securities

    Approximately $560M in total cash, equivalents, and marketable securities. Cash Flows USD Full Year 2025 Business Update COPYRIGHT © ABCELLERA * Restricted cash (including restricted cash in other assets) 14

15. Slide 15: Thank You

    COPYRIGHT © ABCELLERA 15 Full Year 2025 Business Update THANK YOU

AbCellera Biologics — FY2025 Earnings Presentation on 6ix